Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYCR1 | P32322 | 19/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
| ▸ | MAOB | P27338 | 2/20 | 0.72 |
| ▸ | USP2 | O75604 | 1/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.72 |
| ▸ | TSHR | P16473 | 1/20 | 0.72 |
| ▸ | MAOA | P21397 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | BLM | P54132 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pargyline SCHEMBL2045 | 0.84 | PYCR1 (1.00) | PYCR1LMNAMAOBUSP2CYP3A4 | |
| Pargyline SCHEMBL18036659 | 0.84 | PYCR1 (1.00) | PYCR1LMNAMAOBUSP2CYP3A4 | |
| Pargyline SCHEMBL121111 | 0.83 | LMNA (1.00) | PYCR1LMNAMAOBUSP2CYP3A4 | |
| Pargyline SCHEMBL7363311 | 0.83 | PYCR1 (0.96) | PYCR1LMNAMAOBUSP2CYP3A4 | |
| SCHEMBL14125330 | 0.81 | PYCR1 (0.66) | PYCR1LMNAMAOBUSP2CYP3A4 | |
| SCHEMBL14125331 | 0.80 | PYCR1 (0.64) | PYCR1LMNAMAOBUSP2CYP3A4 | |
| Pargyline SCHEMBL2657939 | 0.78 | PYCR1 (0.86) | PYCR1LMNAMAOBUSP2CYP3A4 | |
| SCHEMBL28636497 | 0.77 | ALDH1A1 (0.64) | LMNACYP3A4TSHRALDH1A1 | |
| SCHEMBL8244727 | 0.75 | PYCR1 (0.72) | PYCR1LMNAMAOBUSP2CYP3A4 | |
| SCHEMBL10033809 | 0.75 | PYCR1 (1.00) | PYCR1LMNAMAOBUSP2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2668186-B1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES | SK BIOPHARMACEUTICALS CO LTD (KR) | 2017-05-03 | — | — | EP | disclosed |
| US-8716309-B2 | Pharmaceutical composition comprising pyridone derivatives | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-05-06 | — | — | US | disclosed |
| EP-2668186-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES | SK Biopharmaceuticals Co., Ltd. (KR) | 2013-12-04 | — | — | EP | disclosed |
| US-20130317059-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2013-11-28 | — | — | US | disclosed |
| WO-2012102580-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2012-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130317059-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES | PLPBP, PDXK, PIR | PYCR1 339/4885LMNA 2543/4885MAOB 535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.